<Record>
<Term>Ibritumomab Tiuxetan</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<SemanticType>Organic Chemical</SemanticType>
<ParentTerm>Immunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Biological Response Modifier/Immunoconjugate/Ibritumomab Tiuxetan</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Ibritumomab Tiuxetan</BroaderTerm>
<BroaderTerm>Immunoconjugate</BroaderTerm>
<BroaderTerm>Biological Response Modifier</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>IBRITUMOMAB TIUXETAN</Synonym>
<Synonym>Ibritumomab tiuxetan</Synonym>
<Synonym>Ibritumomab Tiuxetan</Synonym>
<Synonym>Zevalin</Synonym>
<Description>An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes.</Description>
<Source>FDA Registry</Source>
<Source>NCI Thesaurus</Source>
</Record>
